HRP20240501T1 - Derivati pirido[2,3-d]pirimidina kao inhibitori replikacije virusa humane imunodeficijencije - Google Patents
Derivati pirido[2,3-d]pirimidina kao inhibitori replikacije virusa humane imunodeficijencije Download PDFInfo
- Publication number
- HRP20240501T1 HRP20240501T1 HRP20240501TT HRP20240501T HRP20240501T1 HR P20240501 T1 HRP20240501 T1 HR P20240501T1 HR P20240501T T HRP20240501T T HR P20240501TT HR P20240501 T HRP20240501 T HR P20240501T HR P20240501 T1 HRP20240501 T1 HR P20240501T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- agent
- use according
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 159000000018 pyrido[2,3-d]pyrimidines Chemical class 0.000 title 1
- 230000029812 viral genome replication Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 15
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 208000031886 HIV Infections Diseases 0.000 claims 3
- 208000037357 HIV infectious disease Diseases 0.000 claims 3
- 229950005928 cabotegravir Drugs 0.000 claims 3
- WCWSTNLSLKSJPK-LKFCYVNXSA-N cabotegravir Chemical compound C([C@H]1OC[C@@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F WCWSTNLSLKSJPK-LKFCYVNXSA-N 0.000 claims 3
- 229960002542 dolutegravir Drugs 0.000 claims 3
- RHWKPHLQXYSBKR-BMIGLBTASA-N dolutegravir Chemical compound C([C@@H]1OCC[C@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F RHWKPHLQXYSBKR-BMIGLBTASA-N 0.000 claims 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 3
- -1 doravirin Chemical compound 0.000 claims 2
- SWMDAPWAQQTBOG-UHFFFAOYSA-N fostemsavir Chemical compound C1=2N(COP(O)(O)=O)C=C(C(=O)C(=O)N3CCN(CC3)C(=O)C=3C=CC=CC=3)C=2C(OC)=CN=C1N1C=NC(C)=N1 SWMDAPWAQQTBOG-UHFFFAOYSA-N 0.000 claims 2
- 229950010812 fostemsavir Drugs 0.000 claims 2
- 238000010255 intramuscular injection Methods 0.000 claims 2
- 239000007927 intramuscular injection Substances 0.000 claims 2
- 229960001627 lamivudine Drugs 0.000 claims 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 2
- 238000010254 subcutaneous injection Methods 0.000 claims 2
- 239000007929 subcutaneous injection Substances 0.000 claims 2
- 229960004556 tenofovir Drugs 0.000 claims 2
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 2
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 claims 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 claims 1
- 229940126250 GSK3640254 Drugs 0.000 claims 1
- YFSNREBZTKMFEB-DHGHKPCRSA-N [H][C@]12[C@@H](CC[C@@]1(CC[C@]1(C)[C@]2([H])CC[C@]2([H])[C@@]3(C)CC=C(C4=CC[C@](CF)(CC4)C(O)=O)C(C)(C)[C@]3([H])CC[C@@]12C)NCCN1CCS(=O)(=O)CC1)C(C)=C Chemical compound [H][C@]12[C@@H](CC[C@@]1(CC[C@]1(C)[C@]2([H])CC[C@]2([H])[C@@]3(C)CC=C(C4=CC[C@](CF)(CC4)C(O)=O)C(C)(C)[C@]3([H])CC[C@@]12C)NCCN1CCS(=O)(=O)CC1)C(C)=C YFSNREBZTKMFEB-DHGHKPCRSA-N 0.000 claims 1
- 229960004748 abacavir Drugs 0.000 claims 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims 1
- 229960003277 atazanavir Drugs 0.000 claims 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 claims 1
- 229950004159 bictegravir Drugs 0.000 claims 1
- SOLUWJRYJLAZCX-LYOVBCGYSA-N bictegravir Chemical compound C([C@H]1O[C@@H]2CC[C@@H](C2)N1C(=O)C1=C(C2=O)O)N1C=C2C(=O)NCC1=C(F)C=C(F)C=C1F SOLUWJRYJLAZCX-LYOVBCGYSA-N 0.000 claims 1
- 229960005107 darunavir Drugs 0.000 claims 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 claims 1
- 229960004710 maraviroc Drugs 0.000 claims 1
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 229960001355 tenofovir disoproxil Drugs 0.000 claims 1
- JFVZFKDSXNQEJW-CQSZACIVSA-N tenofovir disoproxil Chemical compound N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N JFVZFKDSXNQEJW-CQSZACIVSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863406P | 2019-06-19 | 2019-06-19 | |
| PCT/IB2020/055653 WO2020254985A1 (en) | 2019-06-19 | 2020-06-17 | Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication |
| EP20743783.1A EP3986561B1 (en) | 2019-06-19 | 2020-06-17 | Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240501T1 true HRP20240501T1 (hr) | 2024-07-05 |
Family
ID=71738195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240501TT HRP20240501T1 (hr) | 2019-06-19 | 2020-06-17 | Derivati pirido[2,3-d]pirimidina kao inhibitori replikacije virusa humane imunodeficijencije |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US12129255B2 (https=) |
| EP (1) | EP3986561B1 (https=) |
| JP (1) | JP7628512B2 (https=) |
| KR (1) | KR102932817B1 (https=) |
| CN (2) | CN119039288A (https=) |
| AR (1) | AR119174A1 (https=) |
| AU (1) | AU2020295793B2 (https=) |
| BR (1) | BR112021025655A2 (https=) |
| CL (1) | CL2021003388A1 (https=) |
| CO (1) | CO2021017479A2 (https=) |
| CR (1) | CR20210664A (https=) |
| DK (1) | DK3986561T3 (https=) |
| ES (1) | ES2974541T3 (https=) |
| FI (1) | FI3986561T3 (https=) |
| HR (1) | HRP20240501T1 (https=) |
| HU (1) | HUE065762T2 (https=) |
| IL (1) | IL288750B2 (https=) |
| LT (1) | LT3986561T (https=) |
| MA (1) | MA56526B1 (https=) |
| MD (1) | MD3986561T2 (https=) |
| MX (1) | MX2021016149A (https=) |
| MY (1) | MY206712A (https=) |
| PE (1) | PE20220510A1 (https=) |
| PH (1) | PH12021553180A1 (https=) |
| PL (1) | PL3986561T3 (https=) |
| PT (1) | PT3986561T (https=) |
| RS (1) | RS65304B1 (https=) |
| SI (1) | SI3986561T1 (https=) |
| SM (1) | SMT202400153T1 (https=) |
| TW (1) | TWI850403B (https=) |
| UA (1) | UA128967C2 (https=) |
| UY (1) | UY38755A (https=) |
| WO (1) | WO2020254985A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021004593A (es) | 2018-10-24 | 2021-06-15 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicacion del virus de la inmunodeficiencia humana. |
| LT3986561T (lt) | 2019-06-19 | 2024-04-25 | VIIV Healthcare UK (No.5) Limited | Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai |
| WO2020254559A1 (en) | 2019-06-19 | 2020-12-24 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US20220347174A1 (en) * | 2019-10-01 | 2022-11-03 | Viiv Healthcare Company | Method for treating HIV with Cabotegravir and Rilpivirine |
| UY38982A (es) * | 2019-12-09 | 2021-06-30 | Viiv Healthcare Co | Composiciones farmacéuticas |
| KR20220151655A (ko) * | 2020-03-06 | 2022-11-15 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제 |
| CN115397424A (zh) * | 2020-04-15 | 2022-11-25 | Viiv保健英国第五有限公司 | 人类免疫缺陷病毒复制的抑制剂 |
| US20240423985A1 (en) * | 2021-10-13 | 2024-12-26 | Viiv Healthcare Uk (No.5) Limit-Ed | Inhibitors of human immunodeficiency virus replication |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| AR132951A1 (es) | 2023-06-15 | 2025-08-13 | Viiv Healthcare Uk No 5 Ltd | Métodos e intermedios para preparar compuestos |
| US12594276B2 (en) | 2024-02-05 | 2026-04-07 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030207910A1 (en) | 2001-02-02 | 2003-11-06 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| IL157029A0 (en) | 2001-02-02 | 2004-02-08 | Bristol Myers Squibb Co | Azaindoleoxoacetic piperazine derivatives and pharmaceutical compositions containing the same |
| CN102143962B (zh) * | 2008-07-02 | 2015-03-11 | 爱维艾珂瑟有限公司 | 具有抗病毒特性的化合物 |
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| EP2729448B1 (en) | 2011-07-06 | 2015-09-09 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| CA2896244C (en) | 2013-01-09 | 2017-07-04 | Gilead Sciences, Inc. | 5-membered heteroaryls and their use as antiviral agents |
| CA2897268C (en) | 2013-01-09 | 2018-12-04 | Gilead Sciences, Inc. | Therapeutic compounds for the treatment of viral infections |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| WO2015130964A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| PT3186239T (pt) | 2014-08-29 | 2019-01-10 | Gilead Sciences Inc | Agentes antirretrovirais |
| KR20230011471A (ko) | 2016-08-19 | 2023-01-20 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물 |
| EP3507288B1 (en) * | 2016-09-02 | 2020-08-26 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| TW201906834A (zh) * | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| MX2021004593A (es) * | 2018-10-24 | 2021-06-15 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicacion del virus de la inmunodeficiencia humana. |
| UY38559A (es) | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| LT3986561T (lt) | 2019-06-19 | 2024-04-25 | VIIV Healthcare UK (No.5) Limited | Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai |
-
2020
- 2020-06-17 LT LTEPPCT/IB2020/055653T patent/LT3986561T/lt unknown
- 2020-06-17 MA MA56526A patent/MA56526B1/fr unknown
- 2020-06-17 PH PH1/2021/553180A patent/PH12021553180A1/en unknown
- 2020-06-17 ES ES20743783T patent/ES2974541T3/es active Active
- 2020-06-17 EP EP20743783.1A patent/EP3986561B1/en active Active
- 2020-06-17 CN CN202410979514.XA patent/CN119039288A/zh active Pending
- 2020-06-17 TW TW109120334A patent/TWI850403B/zh active
- 2020-06-17 RS RS20240309A patent/RS65304B1/sr unknown
- 2020-06-17 MD MDE20220479T patent/MD3986561T2/ro unknown
- 2020-06-17 UY UY0001038755A patent/UY38755A/es unknown
- 2020-06-17 SM SM20240153T patent/SMT202400153T1/it unknown
- 2020-06-17 US US17/268,107 patent/US12129255B2/en active Active
- 2020-06-17 MX MX2021016149A patent/MX2021016149A/es unknown
- 2020-06-17 UA UAA202200207A patent/UA128967C2/uk unknown
- 2020-06-17 BR BR112021025655A patent/BR112021025655A2/pt unknown
- 2020-06-17 FI FIEP20743783.1T patent/FI3986561T3/fi active
- 2020-06-17 PL PL20743783.1T patent/PL3986561T3/pl unknown
- 2020-06-17 HU HUE20743783A patent/HUE065762T2/hu unknown
- 2020-06-17 AR ARP200101700A patent/AR119174A1/es unknown
- 2020-06-17 CN CN202080052305.0A patent/CN114245795B/zh active Active
- 2020-06-17 KR KR1020227001501A patent/KR102932817B1/ko active Active
- 2020-06-17 JP JP2021575482A patent/JP7628512B2/ja active Active
- 2020-06-17 AU AU2020295793A patent/AU2020295793B2/en active Active
- 2020-06-17 SI SI202030385T patent/SI3986561T1/sl unknown
- 2020-06-17 CR CR20210664A patent/CR20210664A/es unknown
- 2020-06-17 MY MYPI2021007563A patent/MY206712A/en unknown
- 2020-06-17 IL IL288750A patent/IL288750B2/en unknown
- 2020-06-17 PT PT207437831T patent/PT3986561T/pt unknown
- 2020-06-17 HR HRP20240501TT patent/HRP20240501T1/hr unknown
- 2020-06-17 DK DK20743783.1T patent/DK3986561T3/da active
- 2020-06-17 WO PCT/IB2020/055653 patent/WO2020254985A1/en not_active Ceased
- 2020-06-17 PE PE2021002114A patent/PE20220510A1/es unknown
-
2021
- 2021-12-17 CL CL2021003388A patent/CL2021003388A1/es unknown
- 2021-12-20 CO CONC2021/0017479A patent/CO2021017479A2/es unknown
-
2024
- 2024-09-18 US US18/888,497 patent/US20250019383A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240501T1 (hr) | Derivati pirido[2,3-d]pirimidina kao inhibitori replikacije virusa humane imunodeficijencije | |
| JP7330312B2 (ja) | Ｈｉｖを治療するためのトール様受容体の調節因子 | |
| HRP20240733T1 (hr) | Spojevi i postupci za liječenje virusnih infekcija | |
| HRP20231018T1 (hr) | Terapeutski spojevi korisni za profilaktičko ili terapijsko liječenje hiv virusne infekcije | |
| HRP20221074T1 (hr) | Premošteni triciklički spojevi karbamoilpiridona i njihove farmaceutske uporabe | |
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| HRP20250480T1 (hr) | Kombinacija dasatiniba i adagrasiba za primjenu u liječenju nesitnostaničnog raka pluća | |
| AU2013336491B2 (en) | Pharmaceutical antiretroviral composition | |
| HRP20221263T1 (hr) | Ciklički di-nukleotidni spojevi i postupci uporabe | |
| HRP20241051T1 (hr) | Premošteni spojevi tricikličkog karbamoilpiridona i njihove uporabe | |
| HRP20211543T1 (hr) | Derivati kinazolina koji se koriste za liječenje hiv-a | |
| FI3936130T3 (fi) | Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon | |
| HRP20250266T1 (hr) | Nukleotid hemi-sulfat sol za liječenje virusa hepatitisa c | |
| HRP20241221T1 (hr) | POLICIKLIČNI KARBAMOILPIRIDONSKI DERIVATI ZA LIJEČENJE HIV-a | |
| JP2015505565A5 (https=) | ||
| JP2015501845A5 (https=) | ||
| JP2019511542A5 (https=) | ||
| RU2018132408A (ru) | Фармацевтические композиции, содержащие антиретровирусное лекарство и улучшитель фармакокинетики | |
| AU2016330895A1 (en) | Compounds and combinations for the treatment of HIV | |
| JP2016516773A5 (https=) | ||
| HRP20211749T1 (hr) | Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom | |
| HRP20191019T1 (hr) | Kombinacijska terapija konjugatom protutijela i lijeka anti-her2 i inhibitorom bcl-2 | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| JP2016505050A5 (https=) | ||
| JP7313438B2 (ja) | Ｈｉｖの予防のためのインテグラーゼ阻害剤 |